HomeToday’s HighlightsAmgen and UCB granted FDA approval of Evenity for osteoporosis in menopausal women at risk of bone fracture Amgen and UCB granted FDA approval of Evenity for osteoporosis in menopausal women at risk of bone fracture Today’s Highlights April 10, 2019 Amgen and UDB Granted FDA Approval of Evenity™ Amgen (AMGN) and UCB Pharmaceuticals (This content is for paid subscribers. Please click here to subscribe or here to log in. Today’s Highlights Amgen (AMGN), UCB Pharmaceuticals (UCB) April 10, 2019 Tweet Pin It Other Articles CytomX is Rallying Today! The Firm Will Report Q1 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024 May 1, 2024 0 TG Therapeutics Stock Price is Rising as Q1 Revenues from BRIUMVI U.S. Have Exceeded Expectations May 1, 2024 0 Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer April 30, 2024 0 U.S. FDA Approved Pfizer’s BEQVEZ™ – A One-Time Gene Therapy for Adults with Hemophilia B April 26, 2024 0